173 related articles for article (PubMed ID: 37100457)
21. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
23. Construction and validation of a novel prognostic model using the cellular senescence-associated long non-coding RNA in gastric cancer: a biological analysis.
Wang G; Mao Z; Zhou X; Zou Y; Zhao M
J Gastrointest Oncol; 2022 Aug; 13(4):1640-1655. PubMed ID: 36092333
[TBL] [Abstract][Full Text] [Related]
24. Pyroptosis, apoptosis, and necroptosis molecular subtype derived prognostic signature universal applicable for gastric cancer-A large sample and multicenter retrospective analysis.
Huo J; Xie W; Fan X; Sun P
Comput Biol Med; 2022 Oct; 149():106037. PubMed ID: 36044785
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study.
Huo J; Fan X; Sun W; Sun P
J Immunother; 2023 Oct; 46(8):323-332. PubMed ID: 37469271
[TBL] [Abstract][Full Text] [Related]
26. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.
Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M
Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of 1804 samples of six centers to construct and validate a robust immune-related prognostic signature associated with stromal cell abundance in tumor microenvironment for gastric cancer.
Huo J; Guan G; Cai J; Wu L
World J Surg Oncol; 2022 Jan; 20(1):4. PubMed ID: 34983559
[TBL] [Abstract][Full Text] [Related]
28. Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas.
Wang X; Zhang W; Guo Y; Zhang Y; Bai X; Xie Y
World J Surg Oncol; 2023 Feb; 21(1):61. PubMed ID: 36823639
[TBL] [Abstract][Full Text] [Related]
29. A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer.
Zhao E; Zhou C; Chen S
Clin Transl Oncol; 2021 Feb; 23(2):265-274. PubMed ID: 32519178
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of anoikis-associated gene SNCG as a prognostic biomarker in gastric cancer.
Li Y; Pan Q; Cheng M; Wu Z
Aging (Albany NY); 2023 Mar; 15(7):2541-2553. PubMed ID: 36996495
[TBL] [Abstract][Full Text] [Related]
31. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
32. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.
Liu SJ; Yang YB; Zhou JX; Lin YJ; Pan YL; Pan JH
Dis Markers; 2021; 2021():2385406. PubMed ID: 34868391
[TBL] [Abstract][Full Text] [Related]
33. Eleven immune-gene pairs signature associated with TP53 predicting the overall survival of gastric cancer: a retrospective analysis of large sample and multicenter from public database.
Huo J; Wu L; Zang Y
J Transl Med; 2021 Apr; 19(1):183. PubMed ID: 33926488
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.
Chen T; Yang C; Dou R; Xiong B
Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341
[TBL] [Abstract][Full Text] [Related]
35. Lipid Metabolic-Related Signature CYP19A1 is a Potential Biomarker for Prognosis and Immune Cell Infiltration in Gastric Cancer.
Wang N; Huang X; Long Q
J Inflamm Res; 2022; 15():5075-5088. PubMed ID: 36091333
[TBL] [Abstract][Full Text] [Related]
36. A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients.
Cao W; Zhou W; Li M; Zhang Z; Zhang X; Yang K; Yang S; Cao G; Chen B; Xiong M
Front Immunol; 2022; 13():951135. PubMed ID: 36483555
[TBL] [Abstract][Full Text] [Related]
37. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
Front Immunol; 2022; 13():854785. PubMed ID: 35392086
[TBL] [Abstract][Full Text] [Related]
38. PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Liu B; Xiao X; Lin Z; Lou Y; Zhao L
Cancer Biomark; 2022; 34(2):251-264. PubMed ID: 34958001
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and the Immune Microenvironment in Gastric Cancer.
Wang F; Chen C; Chen WP; Li ZL; Cheng H
Biomed Res Int; 2021; 2021():6014202. PubMed ID: 34708125
[TBL] [Abstract][Full Text] [Related]
40. A Robust Circular RNA-Associated Three-Gene Prognostic Signature for Patients with Gastric Cancer.
Li Y; Li R; Wang X; Yuan Y; Zhang Y
Biomed Res Int; 2021; 2021():6633289. PubMed ID: 33969120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
